Amgen Inc. (NASDAQ:AMGN) – Gabelli decreased their FY2018 earnings per share estimates for Amgen in a report released on Wednesday. Gabelli analyst J. He now expects that the firm will post earnings of $13.00 per share for the year, down from their prior estimate of $13.05. Gabelli has a “Hold” rating on the stock. Gabelli also issued estimates for Amgen’s FY2020 earnings at $12.15 EPS.
Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same period last year, the company posted $2.57 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year.
Several other research analysts have also commented on AMGN. Vetr lowered shares of Amgen from a “hold” rating to a “sell” rating and set a $166.35 price target for the company. in a report on Monday, August 1st. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $204.00 price target on shares of Amgen in a report on Thursday, September 8th. Cowen and Company reaffirmed a “buy” rating on shares of Amgen in a report on Monday, September 19th. Jefferies Group reaffirmed a “buy” rating and issued a $187.00 price target on shares of Amgen in a report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $193.00 price target on shares of Amgen in a report on Thursday, July 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $184.51.
Shares of Amgen (NASDAQ:AMGN) traded down 2.51% on Thursday, reaching $165.45. 3,803,721 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $172.00 and its 200-day moving average price is $160.83. Amgen has a 1-year low of $135.64 and a 1-year high of $176.85. The company has a market capitalization of $123.82 billion, a P/E ratio of 16.93 and a beta of 0.87.
A number of hedge funds and other institutional investors have recently made changes to their positions in AMGN. Kelman Lazarov Inc. bought a new position in shares of Amgen during the first quarter worth approximately $252,000. FirstMerit Bank N A Trustee increased its stake in Amgen by 5.3% in the first quarter. FirstMerit Bank N A Trustee now owns 32,630 shares of the medical research company’s stock valued at $4,893,000 after buying an additional 1,632 shares in the last quarter. Private Trust Co. NA increased its stake in Amgen by 1.8% in the first quarter. Private Trust Co. NA now owns 3,236 shares of the medical research company’s stock valued at $485,000 after buying an additional 58 shares in the last quarter. Sigma Planning Corp increased its stake in Amgen by 7.6% in the first quarter. Sigma Planning Corp now owns 6,278 shares of the medical research company’s stock valued at $941,000 after buying an additional 442 shares in the last quarter. Finally, McQueen Ball & Associates Inc. increased its stake in Amgen by 1.7% in the first quarter. McQueen Ball & Associates Inc. now owns 10,642 shares of the medical research company’s stock valued at $1,596,000 after buying an additional 182 shares in the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
In other news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were issued a dividend of $1.00 per share. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.42%. Amgen’s dividend payout ratio is currently 40.90%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.